Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.65)
# 832
Out of 5,014 analysts
226
Total ratings
49.26%
Success rate
7.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $65 → $77 | $45.76 | +68.27% | 3 | Sep 29, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $109 → $122 | $100.21 | +21.74% | 13 | Sep 25, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $163 → $167 | $138.15 | +20.88% | 10 | Sep 24, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $44.46 | +77.69% | 5 | Sep 17, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $19 → $18 | $8.89 | +102.47% | 4 | Sep 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $158 → $163 | $138.47 | +17.72% | 29 | Sep 5, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $71 | $66.01 | +7.56% | 13 | Aug 20, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Overweight | $35 → $28 | $7.05 | +297.16% | 7 | Aug 18, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $20 → $21 | $12.16 | +72.70% | 4 | Aug 18, 2025 | |
| ERAS Erasca | Downgrades: Equal-Weight | $4 → $2 | $2.45 | -18.37% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $8.87 | +46.56% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $8.27 | +1,205.93% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $31.66 | +73.72% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $20.63 | +16.34% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $70.75 | +20.14% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $22.83 | +18.27% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $5.45 | -8.26% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $60.31 | +11.09% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.54 | +309.84% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $1.40 | +185.71% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.89 | +111.64% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $6.24 | +124.36% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $4.59 | +8.93% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $2.46 | +22.20% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.83 | +665.03% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $2.14 | +367.29% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $38.57 | -42.96% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $17.23 | +761.87% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.48 | +3,962.29% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $5.15 | +16.50% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $6.84 | +9,374.93% | 6 | May 8, 2020 |
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Overweight
Price Target: $65 → $77
Current: $45.76
Upside: +68.27%
Rhythm Pharmaceuticals
Sep 25, 2025
Maintains: Overweight
Price Target: $109 → $122
Current: $100.21
Upside: +21.74%
Jazz Pharmaceuticals
Sep 24, 2025
Maintains: Overweight
Price Target: $163 → $167
Current: $138.15
Upside: +20.88%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $44.46
Upside: +77.69%
enGene Holdings
Sep 12, 2025
Maintains: Overweight
Price Target: $19 → $18
Current: $8.89
Upside: +102.47%
Neurocrine Biosciences
Sep 5, 2025
Maintains: Overweight
Price Target: $158 → $163
Current: $138.47
Upside: +17.72%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $76 → $71
Current: $66.01
Upside: +7.56%
Cullinan Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $7.05
Upside: +297.16%
Contineum Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $12.16
Upside: +72.70%
Erasca
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $2.45
Upside: -18.37%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $8.87
Upside: +46.56%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $8.27
Upside: +1,205.93%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $31.66
Upside: +73.72%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $20.63
Upside: +16.34%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $70.75
Upside: +20.14%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $22.83
Upside: +18.27%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $5.45
Upside: -8.26%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $60.31
Upside: +11.09%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $8.54
Upside: +309.84%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $1.40
Upside: +185.71%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.89
Upside: +111.64%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $6.24
Upside: +124.36%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $4.59
Upside: +8.93%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.46
Upside: +22.20%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.83
Upside: +665.03%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $2.14
Upside: +367.29%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $38.57
Upside: -42.96%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $17.23
Upside: +761.87%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.48
Upside: +3,962.29%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $5.15
Upside: +16.50%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $6.84
Upside: +9,374.93%